Abiopharma

News list

Director Stauch John L 🟡 adjusted position in 5.3K shares (2 derivative) of DELUXE CORP (DLX) Transaction Date: Apr 23, 2026 | Filing ID: 000002

Full text

News bot April 27, 2026, 2:37 p.m.
🔍 Stauch John L (Director)

Company: DELUXE CORP (DLX)

Report Date: 2026-04-23
Transaction Summary:
- Total transactions: 3
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 15,635
- Total shares sold: 10,349
Detailed Transactions and Holdings:
- Acquired 10,349 shares of Common Stock (Direct)
  Date: 2026-04-23 | Code: M | equity_swap_involved: 0 | shares_owned_after: 77,650.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 5,286 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-23 | Code: A | Expires: 2027-04-24 | Exercise: 2027-04-24 | equity_swap_involved: 0 | shares_owned_after: 5,286.00 | transaction_form_type: 4 | Footnotes: F2
- Sold 10,349 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-23 | Code: M | Expires: 2026-04-23 | Exercise: 2026-04-23 | equity_swap_involved: 0 | transaction_form_type: 4
Footnotes:
- F1: Transaction reflects vesting and conversion into shares on a one-for-one basis of restricted stock units previously awarded.
- F2: Restricted stock units vest on the date of our 2027 annual shareholder meeting, which is expected to be April 22, 2027.